Skip to main content
Figure 4 | Arthritis Research & Therapy

Figure 4

From: Comparative evaluation of the effects of treatment with tocilizumab and TNF-α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients

Figure 4

Comparison of effects of tocilizumab and tumor necrosis factor α inhibitors on rheumatoid arthritis disease activity during 16-week treatment. (A) C-reactive protein (CRP). (B) Vascular endothelial growth factor (VEGF). (C) Disease Activity Score in 28 joints (DAS28), tender joint count (TJC), Visual Analogue Scale (VAS) score and rheumatoid factor (RF). TCZ, tocilizumab; TNFi, tumor necrosis factor α inhibitors. Values are means and SEM. *P < 0.01, vs. baseline by paired t-test. #P < 0.01 and $P < 0.05 by paired t-test for comparison of changes from baseline between the two groups at 16 weeks.

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us